|
1
|
Hazard JB, Hawk WA and Crile G Jr:
Medullary (solid) carcinoma of the thyroid; a clinicopathologic
entity. J Clin Endocrinol Metab. 19:152–161. 1959. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006.
|
|
3
|
Girelli ME, Nacamulli D, Pelizzo MR, et
al: Medullary thyroid carcinoma: clinical features and long-term
follow-up of seventy-eight patients treated between 1969 and 1986.
Thyroid. 8:517–523. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Modigliani E, Cohen R, Campos JM, et al:
Prognostic factors for survival and for biochemical cure in
medullary thyroid carcinoma: results in 899 patients. The GETC
Study Group Groupe d’étude des tumeurs à calcitonine. Clin
Endocrinol (Oxf). 48:265–273. 1998.PubMed/NCBI
|
|
5
|
Droz JP, Schlumberger M, Rougier P, et al:
Chemotherapy in metastatic nonanaplastic thyroid cancer: experience
at the Institut Gustave-Roussy. Tumori. 76:480–483. 1990.PubMed/NCBI
|
|
6
|
O’Doherty MJ and Coakley AJ: Drug therapy
alternatives in the treatment of thyroid cancer. Drugs. 55:801–812.
1998.PubMed/NCBI
|
|
7
|
Soumaoro LT, Uetake H, Higuchi T, Takagi
Y, Enomoto M and Sugihara K: Cyclooxygenase-2 expression: a
significant prognostic indicator for patients with colorectal
cancer. Clin Cancer Res. 10:8465–8471. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ogunwobi OO and Liu C: Hepatocyte growth
factor upregulation promotes carcinogenesis and
epithelial-mesenchyma transition in hepatocellular carcinoma via
Akt and COX-2 pathways. Clin Exp Metastasis. 28:721–731. 2011.
View Article : Google Scholar
|
|
9
|
Thiel A, Mrena J and Ristimäki A:
Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev.
30:387–395. 2011. View Article : Google Scholar
|
|
10
|
Saad MF, Ordonez NG, Rashid RK, et al:
Medullary carcinoma of the thyroid. A study of the clinical
features and prognostic factors in 161 patients. Medicine
(Baltimore). 63:319–342. 1984.PubMed/NCBI
|
|
11
|
Pelizzo MR, Boschin IM, Bernante P, et al:
Natural history, diagnosis, treatment and outcome of medullary
thyroid cancer: 37 years experience on 157 patients. Eur J Surg
Oncol. 33:493–497. 2007.PubMed/NCBI
|
|
12
|
Chen WT, Hung WC, Kang WY, et al:
Overexpression of cyclooxygenase-2 in urothelial carcinoma in
conjunction with tumor-associated-macrophage infiltration,
hypoxiainducible factor-1alpha expression, and tumor angiogenesis.
APMIS. 117:176–184. 2009. View Article : Google Scholar
|
|
13
|
Liu H, Xiao J, Yang Y, et al: COX-2
expression is correlated with VEGF-C, lymphangiogenesis and lymph
node metastasis in human cervical cancer. Microvasc Res.
82:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mehar A, Macanas-Pirard P, Mizokami A,
Takahashi Y, Kass GE and Coley HM: The effects of cyclooxygenase-2
expression in prostate cancer cells: modulation of response to
cytotoxic agents. J Pharmacol Exp Ther. 324:1181–1187. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghosh N, Chaki R, Mandal V and Mandal SC:
COX-2 as a target for cancer chemotherapy. Pharmacol Rep.
62:233–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu YL, Kuo YC, Kuo PL, Ng LT, Kuo YH and
Lin CC: Apoptotic effects of extract from Antrodia camphorata
fruiting bodies in human hepatocellular carcinoma cell lines.
Cancer Lett. 221:77–89. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lou J, Fatima N, Xiao Z, et al: Proteomic
profiling identifies cyclooxygenase-2-independent global proteomic
changes by celecoxib in colorectal cancer cells. Cancer Epidemiol
Biomarkers Prev. 15:1598–1606. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abou-Issa HM, Alshafie GA, Seibert K, Koki
AT, Masferrer JL and Harris RE: Dose-response effects of the COX-2
inhibitor, celecoxib, on the chemoprevention of mammary
carcinogenesis. Anticancer Res. 21:3425–3432. 2001.PubMed/NCBI
|
|
19
|
Park W, Oh TY, Han JH and Pyo H: Antitumor
enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor,
in a Lewis lung carcinoma expressing Cyclooxygenase-2. J Exp Clin
Cancer Res. 27:662008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai ZJ, Gao J, Li ZF, et al: In vitro and
in vivo antitumor activity of Scutellaria barbate extract on murine
liver cancer. Molecules. 16:4389–4400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tai MH, Weng CH, Mon DP, et al:
Ultraviolet C irradiation induces different expression of
Cyclooxygenase 2 in NIH 3T3 cells and A431 cells: The roles of
COX-2 are different in various cell lines. Int J Mol Sci.
13:4351–4366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jang TJ, Jung HG, Jung KH and OMK:
Chemopreventive effect of celecoxib and expression of
cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat
mammary tumours. Int J Exp Pathol. 83:173–182. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Keller JJ and Giardiello FM:
Chemoprevention strategies using NSAIDs and COX-2 inhibitors.
Cancer Biol Ther. 2(4 Suppl 1): 1–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hilmi I and Goh KL: Chemoprevention of
colorectal cancer with nonsteroidal anti-inflammatory drugs. Chin J
Dig Dis. 7:1–6. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park SW, Kim HS, Hah JW, Jeong WJ, Kim KH
and Sung MW: Celecoxib inhibits cell proliferation through the
activation of ERK and p38 MAPK in head and neck squamous cell
carcinoma cell lines. Anticancer Drugs. 21:823–830. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fischer SM, Hawk ET and Lubet RA: Coxibs
and other nonsteroidal anti-inflammatory drugs in animal models of
cancer chemoprevention. Cancer Prev Res (Phila). 4:1728–1735. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sobolewski C, Cerella C, Dicato M and
Diederich M: Cox-2 inhibitors induce early c-Myc downregulation and
lead to expression of differentiation markers in leukemia cells.
Cell Cycle. 10:2978–2993. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Müller-Decker K and Fürstenberger G: The
cyclooxygenase-2-mediated prostaglandin signaling is causally
related to epithelial carcinogenesis. Mol Carcinog. 46:705–710.
2007.PubMed/NCBI
|
|
29
|
Rasmuson A, Kock A, Fuskevåg OM, et al:
Autocrine prostaglandin E2 signaling promotes tumor cell survival
and proliferation in childhood neuroblastoma. PLoS One.
7:e293312012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pockaj BA, Basu GD, Pathangey LB, et al:
Reduced T-cell and dendritic cell function is related to
cyclooxygenase-2 overexpression and prostaglandin E2 secretion in
patients with breast cancer. Ann Surg Oncol. 11:328–339. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grösch S, Maier TJ, Schiffmann S and
Geisslinger G: Cyclooxygenase-2 (COX-2)-independent
anticarcinogenic effects of selective COX-2 inhibitors. J Natl
Cancer Inst. 98:736–747. 2006.PubMed/NCBI
|
|
32
|
Reddy BS, Hirose Y, Lubet R, et al:
Chemoprevention of colon cancer by specific cyclooxygenase-2
inhibitor, celecoxib, administered during different stages of
carcinogenesis. Cancer Res. 60:293–297. 2000.PubMed/NCBI
|
|
33
|
Rajput S and Mandal M: Antitumor promoting
potential of selected phytochemicals derived from spices: a review.
Eur J Cancer Prev. 21:205–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McNamara DA, Harmey J, Wang JH, Kay E,
Walsh TN and Bouchier-Hayes DJ: Tamoxifen inhibits endothelial cell
proliferation and attenuates VEGF-mediated angiogenesis and
migration in vivo. Eur J Surg Oncol. 27:714–718. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bozbora A, Erbil Y, Türe N, Barbaros U and
Özarmagan S: Role of vascular endothelial growth factor in the
prognosis of papillary thyroid cancer. The Endocrinologist.
16:168–171. 2003. View Article : Google Scholar
|
|
36
|
Bunone G, Vigneri P and Bongarzone I:
Expression of angiogenesis stimulators and inhibitors in human
thyroid tumors and correlation with clinical pathological features.
Am J Pathol. 155:1967–1976. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fenton C, Patel A, Dinauer C, et al: The
expression of vascular endothelial growth factor and the type 1
vascular endothelial growth factor receptor correlate with the size
of papillary thyroid carcinoma in children and young adults.
Thyroid. 10:349–357. 2000. View Article : Google Scholar
|
|
38
|
Kirkpatrick K, Ogunkolade W, Elkak A,
Bustin S, Jenkins P, Ghilchik M and Mokbel K: The mRNA expression
of Cyclooxygenase-2 (COX-2) and vascular endothelial growth factor
(VEGF) in human hreast cancer. Curr Med Res Opin. 18:237–241. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese
JL and Xie K: Celecoxib inhibits vascular endothelial growth factor
expression in and reduces angiogenesis and metastasis of human
pancreatic cancer via suppression of Sp1 transcription factor
activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar
|
